Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib, Dalpiciclib, and Letrozole in ER+/HER2+ Advanced Breast Cancer
NCT07014410Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib, dalpiciclib in breast cancer, sponsored by Zhejiang Cancer Hospital. Started Feb 2023; status: recruiting.
02
Drugs
pyrotinibdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07014410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014410.